^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TrkA receptor antagonist

    Related drugs:
    13d
    AB-106-C205: Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion (clinicaltrials.gov)
    P2, N=14, Terminated, Nuvation Bio Inc. | N=40 --> 14 | Recruiting --> Terminated; The study was discontinued early by the Sponsor for business reasons on 06 Dec 2024
    Enrollment change • Trial termination • Pan tumor
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    Ibtrozi (taletrectinib)
    2ms
    VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (clinicaltrials.gov)
    P1/2, N=242, Recruiting, VM Oncology, LLC | Phase classification: P1 --> P1/2 | N=82 --> 242 | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)
    |
    Keytruda (pembrolizumab) • VMD-928
    3ms
    Targeting ROS1 in NSCLC: Clinical Advances and Future Directions of Taletrectinib. (PubMed, Zhongguo Ying Yong Sheng Li Xue Za Zhi)
    Findings show that taletrectinib has a promising anticancer impact, good CNS penetration, and a solid safety record, especially in patients with brain metastases. These results imply that ROS1-positive cancers may benefit from taletrectinib as a treatment.
    Review • Journal
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    ROS1 positive
    |
    Ibtrozi (taletrectinib)
    4ms
    TRUST-II: Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (clinicaltrials.gov)
    P2, N=217, Active, not recruiting, Nuvation Bio Inc. | Recruiting --> Active, not recruiting | Trial completion date: Jun 2027 --> Dec 2027
    Enrollment closed • Trial completion date
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 fusion
    |
    Ibtrozi (taletrectinib)
    4ms
    Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New trial • Real-world evidence
    |
    Rozlytrek (entrectinib) • Ibtrozi (taletrectinib)
    5ms
    Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) (clinicaltrials.gov)
    P3, N=180, Recruiting, Nuvation Bio Inc.
    New P3 trial
    |
    Ibtrozi (taletrectinib)
    6ms
    Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    Ibtrozi (taletrectinib)
    7ms
    Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression. (PubMed, Cancer Cell)
    We functionally validated 16 drug targets identified through integrated spatial transcriptomics and proteomics. Combined treatment targeting CDK4/6 (milciclib) and FOLR1 (mirvetuximab) achieved significant tumor reduction in vivo, representing a promising therapeutic strategy for LGSC.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • FOLR1 ( Folate receptor alpha ) • CDK4 (Cyclin-dependent kinase 4)
    |
    MET overexpression
    |
    milciclib (TZLS-201)